Austria

Key Insights

1
No psychedelic therapy is broadly approved in Austria; patient access is essentially limited to ketamine/esketamine-based psychiatric use, not classic psychedelics.
2
Austria’s database shows 13 trials, 4 active, with ketamine and esketamine dominating the pipeline; placebo is the only other recorded comparator.
3
Vienna has been a European reference point for ketamine psychiatry, including Medical University-led studies on OCD and treatment-resistant depression.
4
Momentum is concentrated in Vienna’s academic centres, with active ketamine and esketamine trials and a 2026 CoBeNe PhD Academy session signalling continued institutional focus.

Medical Only (Private)

Reimbursed Care Access

Austria maintains a restrictive controlled‑substances framework (Suchtmittelgesetz) that places classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑X, etc.) under criminal control with no routine medical reimbursement; exceptions exist for licensed medical uses of ketamine and for esketamine (Spravato) following EU/EMA authorization. Access to most psychedelics is limited to authorised clinical research or tightly supervised medical contexts (esketamine) or off‑label specialist use (ketamine infusions), and routine coverage by public statutory health insurance is uncommon and depends on case‑by‑case decisions. Clinical trials of psilocybin have been authorised at Austrian sites, but these represent research‑only access pathways rather than reimbursed standard care.

Full guide →